Data show overall survival improvement of 22.5 months with ThermoDox ® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox’s potential for superior efficacy when combined with a well-executed RFA procedure LAWRENCEVILLE, N.J , Aug.

     First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating Losses Will Fund Operations Into 2021 NIH Manuscript Provides Support for ThermoDox’s Potential in the

NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox ® Improves Overall Survival with Significance in Patients with Primary Liver Cancer NIH Analysis Supports the OPTIMA Study Design, Celsion’s Fully Enrolled Global

Presentation Slides Available on Celsion’s Website LAWRENCEVILLE, N.J , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Premal H. Thaker , M.D., MSc., Professor of Obstetrics and Gynecology-Division of Gynecologic Oncology

LAWRENCEVILLE, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2019 and provide an update on its development programs for ThermoDox ® , its

Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces the prescribed number of events has been reached for the first

An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range of Solid Tumors with Multiple Localized Heating Sources LAWRENCEVILLE, N.J , June 20, 2019 (GLOBE

Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J , May 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2019 and provided an update

LAWRENCEVILLE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox ® , its

  Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox ®           Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J , April 17, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical stage oncology drug